The DOT testing taking place at HHS-certified laboratories is a 5-panel testing regimen that tests for 14 drugs. It is easy to be somewhat confused by this, so lets take a look at exactly what it means.
On January 1st, 2018, the DOT renamed ‘Opiates’ to ‘Opioids’, as now this includes semi-synthetic opioids. For the ‘Opioids’, the DOT will continue to expect the use of confirmatory testing when suitable for codeine, morphine, and 6-AM (heroin). Additional confirmatory testing has been added for semi-synthetic opioids Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone (brand names including OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, and Exalgo®).
For “Amphetamines,” the DOT will include confirmatory testing when suitable for amphetamine, methamphetamine, MDMA, MDA; as well initial testing has been added for MDA, whereas MDEA has been removed from this group.
The revised DOT drug testing categories are as follows:
- Marijuana (THC)
- 6-AM (Heroin)
- Phencyclidine (PCP)
The changes for collectors, laboratories, MROs, and employers after January 1st, 2018, are as follows:
- Collectors will continue to check the 5-panel box in Step 1 of the CCF (“THC, COC, PCP, OPI, AMP”).
- Laboratories will continue to report to MROs regarding positive drug test results, and will include confirmed positives for Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone as suitable. Additionally, in semi-annual reports to DOT and employers, laboratories will include confirmed positive totals for Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone under “Opioids” as suitable.
- MROs will continue to report to employers regarding verified positive drug results, and add verified positives for Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone as suitable.
- Employers will continue to report annually (MIS) on the number of verified positive drug test results in each testing category (Marijuana, Cocaine, Amphetamines, Opioids, and PCP).